Introduction: Sepsis is a systemic inflammatory response syndrome caused by infectious diseases, with cytokines possibly having an important role in the disease mechanism. Acrylonitrile-co-methallyl sulfonate surface-treated (AN69ST) membrane is expected to improve the outcomes of patients with sepsis through cytokine adsorption. Objective: This study aimed to investigate the clinical effect of the AN69ST membrane in comparison to standard continuous renal replacement therapy (CRRT) membranes for panperitonitis due to lower gastrointestinal perforation. Methods: Using the Diagnosis Procedure Combination database, we identified adult patients with sepsis due to panperitonitis receiving any CRRT. Propensity score matching was used to compare patients who received CRRT with the AN69ST membrane (AN69ST group) and those who received CRRT with other membranes (non-AN69ST group). The primary outcome measure was in-hospital mortality. Results: A total of 528 and 1,445 patients were included in the AN69ST group and in the non-AN69ST group, respectively. Propensity score matching resulted in 521 pairs. There was no significant difference in in-hospital mortality (32.1 vs. 35.5%; p = 0.265) and 30-day mortality (41.3 vs. 42.8%, p = 0.074) between the AN69ST group and the non-AN69ST group. Conclusion: There is no significant difference in-hospital mortality between CRRT with the AN69ST membrane and CRRT with standard CRRT membranes for panperitonitis due to lower gastrointestinal perforation. These results indicate that the AN69ST membrane is not superior to the standard CRRT membrane.

1.
Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.
Crit Care Med
. 2001 Jul;29(7):1303–10.
2.
Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000.
N Engl J Med
. 2003 Apr;348(16):1546–54.
3.
Remick DG1. Ward PA.Evaluation of endotoxin models for the study of sepsis.
Shock
. 2005;1:7–11.
4.
Kasahara Y, Matsumoto H, Umemura H, Shirafa S, Kuyama T. Idiopathic perforation of the sigmoid colon in Japan.
World J Surg
. 1981 Jan;5(1):125–30.
5.
Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al.; SCCM/ESICM/ACCP/ATS/SIS. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference.
Crit Care Med
. 2003 Apr;31(4):1250–6.
6.
Doi K, Rabb H. Impact of acute kidney injury on distant organ function: recent findings and potential therapeutic targets.
Kidney Int
. 2016 Mar;89(3):555–64.
7.
Oda S, Sadahiro T, Hirayama Y, Nakamura M, Watanabe E, Tateishi Y, et al. Non-renal indications for continuous renal replacement therapy: current status in Japan.
Contrib Nephrol
. 2010;166:47–53.
8.
Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial.
JAMA
. 2009 Jun;301(23):2445–52.
9.
Payen DM, Guilhot J, Launey Y, Lukaszewicz AC, Kaaki M, Veber B, et al.; ABDOMIX Group. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial.
Intensive Care Med
. 2015 Jun;41(6):975–84.
10.
Klein DJ, Foster D, Schorr CA, Kazempour K, Walker PM, Dellinger RP. The EUPHRATES trial (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock): study protocol for a randomized controlled trial.
Trials
. 2014 Jun;15(1):218.
11.
Fujii T, Ganeko R, Kataoka Y, Furukawa TA, Featherstone R, Doi K, et al. Polymyxin B-immobilized hemoperfusion and mortality in critically ill adult patients with sepsis/septic shock: a systematic review with meta-analysis and trial sequential analysis.
Intensive Care Med
. 2018 Feb;44(2):167–78.
12.
Ronco C, Bellomo R, Homel P, Brendolan A, Dan M, Piccinni P, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial.
Lancet
. 2000 Jul;356(9223):26–30.
13.
Bellomo R, Cass A, Cole L, Finfer S, Gallagher M, Lo S, et al.; RENAL Replacement Therapy Study Investigators. Intensity of continuous renal-replacement therapy in critically ill patients.
N Engl J Med
. 2009 Oct;361(17):1627–38.
14.
Palevsky PM, Zhang JH, O’Connor TZ, Chertow GM, Crowley ST, Choudhury D, et al.; VA/NIH Acute Renal Failure Trial Network. Intensity of renal support in critically ill patients with acute kidney injury.
N Engl J Med
. 2008 Jul;359(1):7–20.
15.
Villa G, Zaragoza JJ, Sharma A, Neri M, De Gaudio AR, Ronco C. Cytokine removal with high cut-off membrane: review of literature.
Blood Purif
. 2014;38(3-4):167–73.
16.
Peng Z, Pai P, Hong-Bao L, Rong L, Han-Min W, Chen H. The impacts of continuous veno-venous hemofiltration on plasma cytokines and monocyte human leukocyte antigen-DR expression in septic patients.
Cytokine
. 2010 May;50(2):186–91.
17.
Yumoto M, Nishida O, Moriyama K, Shimomura Y, Nakamura T, Kuriyama N, et al. In vitro evaluation of high mobility group box 1 protein removal with various membranes for continuous hemofiltration.
Ther Apher Dial
. 2011 Aug;15(4):385–93.
18.
Rimmelé T, Assadi A, Cattenoz M, Desebbe O, Lambert C, Boselli E, et al. High-volume haemofiltration with a new haemofiltration membrane having enhanced adsorption properties in septic pigs.
Nephrol Dial Transplant
. 2009 Feb;24(2):421–7.
19.
Kellum JA, Dishart MK. Effect of hemofiltration filter adsorption on circulating IL-6 levels in septic rats.
Crit Care
. 2002 Oct;6(5):429–33.
20.
Doi K, Iwagami M, Yoshida E, Marshall MR. Associations of polyethylenimine-coated AN69ST membrane in continuous renal replacement therapy with the intensive care outcomes: Observations from a claims database from Japan. Blood Purif. 2017;44(3):184–92.
21.
Kobashi S, Maruhashi T, Nakamura T, Hatabayashi E, Kon A. The 28-day survival rates of two cytokine-adsorbing hemofilters for continuous renal replacement therapy: a single-center retrospective comparative study.
Acute Med Surg
. 2018 Dec;6(1):60–7.
22.
Tanaka A, Inaguma D, Nakamura T, Watanabe Y, Ito E, Kamegai N, et al. Effect of continuous hemodiafiltration using an AN69ST membrane in patients with sepsis.
Ren Replace Ther.
2017;3(1):12.
23.
Sumitani M, Uchida K, Yasunaga H, Horiguchi H, Kusakabe Y, Matsuda S, et al. Prevalence of malignant hyperthermia and relationship with anesthetics in Japan: data from the diagnosis procedure combination database.
Anesthesiology
. 2011 Jan;114(1):84–90.
24.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
J Chronic Dis
. 1987;40(5):373–83.
25.
Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.
J Clin Epidemiol
. 1992 Jun;45(6):613–9.
26.
Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.
Med Care
. 2005 Nov;43(11):1130–9.
27.
Yasunaga H, Horiguchi H, Kuwabara K, Matsuda S, Fushimi K, Hashimoto H, et al. Outcomes after laparoscopic or open distal gastrectomy for early-stage gastric cancer: a propensity-matched analysis.
Ann Surg
. 2013 Apr;257(4):640–6.
28.
Ayanian JZ, Landrum MB, Guadagnoli E, Gaccione P. Specialty of ambulatory care physicians and mortality among elderly patients after myocardial infarction.
N Engl J Med
. 2002 Nov;347(21):1678–86.
29.
Griswold ME, Localio AR, Mulrow C. Propensity score adjustment with multilevel data: setting your sites on decreasing selection bias.
Ann Intern Med
. 2010 Mar;152(6):393–5.
30.
Lin MT, Saito H, Fukushima R, Inaba T, Fukatsu K, Inoue T, et al. Route of nutritional supply influences local, systemic, and remote organ responses to intraperitoneal bacterial challenge.
Ann Surg
. 1996 Jan;223(1):84–93.
31.
Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, et al. Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators.
Intensive Care Med
. 2007 Sep;33(9):1563–70.
32.
Hirayama Y, Oda S, Wakabayashi K, Sadahiro T, Nakamura M, Watanabe E, et al. Comparison of interleukin-6 removal properties among hemofilters consisting of varying membrane materials and surface areas: an in vitro study.
Blood Purif
. 2011;31(1-3):18–25.
33.
Hoke TS, Douglas IS, Klein CL, He Z, Fang W, Thurman JM, et al. Acute renal failure after bilateral nephrectomy is associated with cytokine-mediated pulmonary injury.
J Am Soc Nephrol
. 2007 Jan;18(1):155–64.
34.
Andres-Hernando A, Dursun B, Altmann C, Ahuja N, He Z, Bhargava R, et al. Cytokine production increases and cytokine clearance decreases in mice with bilateral nephrectomy.
Nephrol Dial Transplant
. 2012 Dec;27(12):4339–47.
35.
Klein CL, Hoke TS, Fang WF, Altmann CJ, Douglas IS, Faubel S. Interleukin-6 mediates lung injury following ischemic acute kidney injury or bilateral nephrectomy.
Kidney Int
. 2008 Oct;74(7):901–9.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.